Matthew D Blackledge
Overview
Explore the profile of Matthew D Blackledge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donners R, Candito A, Rata M, Sharp A, Messiou C, Koh D, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730599
(1) Background: We assessed the test-re-test repeatability of radiomics in metastatic castration-resistant prostate cancer (mCPRC) bone disease on whole-body diffusion-weighted (DWI) and T1-weighted Dixon MRI. (2) Methods: In 10 mCRPC...
2.
Candito A, Holbrey R, Ribeiro A, Messiou C, Tunariu N, Koh D, et al.
Bioengineering (Basel)
. 2024 Feb;
11(2).
PMID: 38391616
Background: Whole-Body Diffusion-Weighted Imaging (WBDWI) is an established technique for staging and evaluating treatment response in patients with multiple myeloma (MM) and advanced prostate cancer (APC). However, WBDWI scans show...
3.
Kalantar R, Curcean S, Winfield J, Lin G, Messiou C, Blackledge M, et al.
Diagnostics (Basel)
. 2023 Nov;
13(21).
PMID: 37958277
T-weighted magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) are essential components of cervical cancer diagnosis. However, combining these channels for the training of deep learning models is challenging due...
4.
Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge M, Cook G, et al.
JNCI Cancer Spectr
. 2023 Oct;
7(6).
PMID: 37788117
Background: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation Criteria in Solid...
5.
Donners R, Tunariu N, Tovey H, Hall E, Chua S, Cook G, et al.
Eur Radiol
. 2023 Aug;
34(2):1146-1154.
PMID: 37615760
Objectives: To investigate whether baseline 18F-sodium fluoride (NaF) and 18F-choline PET activity is associated with metastatic castration-resistant prostate cancer (mCRPC) global and individual bone metastases' DWI MR imaging response to...
6.
Kalantar R, Hindocha S, Hunter B, Sharma B, Khan N, Koh D, et al.
Sci Rep
. 2023 Jun;
13(1):10568.
PMID: 37386097
Handcrafted and deep learning (DL) radiomics are popular techniques used to develop computed tomography (CT) imaging-based artificial intelligence models for COVID-19 research. However, contrast heterogeneity from real-world datasets may impair...
7.
Knill A, Blackledge M, Curcean A, Larkin J, Turajlic S, Riddell A, et al.
Eur Radiol
. 2022 Sep;
33(2):863-871.
PMID: 36169688
Objective: To establish optimised diffusion weightings ('b-values') for acquisition of whole-body diffusion-weighted MRI (WB-DWI) for estimation of the apparent diffusion coefficient (ADC) in patients with metastatic melanoma (MM). Existing recommendations...
8.
Zormpas-Petridis K, Tunariu N, Collins D, Messiou C, Koh D, Blackledge M
Comput Biol Med
. 2022 Sep;
149:106091.
PMID: 36115298
Purpose: To use deep learning to calculate the uncertainty in apparent diffusion coefficient (σADC) voxel-wise measurements to clinically impact the monitoring of treatment response and improve the quality of ADC...
9.
Thrussell I, Winfield J, Orton M, Miah A, Zaidi S, Arthur A, et al.
Front Oncol
. 2022 Aug;
12:899180.
PMID: 35924167
Background: Size-based assessments are inaccurate indicators of tumor response in soft-tissue sarcoma (STS), motivating the requirement for new response imaging biomarkers for this rare and heterogeneous disease. In this study,...
10.
Arthur A, Johnston E, Winfield J, Blackledge M, Jones R, Huang P, et al.
Front Oncol
. 2022 Jul;
12:892620.
PMID: 35847882
A shift in radiology to a data-driven specialty has been unlocked by synergistic developments in imaging biomarkers (IB) and computational science. This is advancing the capability to deliver "virtual biopsies"...